{"resourceType":"Observation","id":"TxImp05","meta":{"profile":["http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"]},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">Poor metabolizer of Amitriptyline</div>"},"extension":[{"url":"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-artifact","valueRelatedArtifact":{"type":"citation","url":"https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"}}],"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory"}]}],"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"therapeutic-implication"}]},"derivedFrom":[{"reference":"Observation/Pgx-geno-1001"}],"component":[{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7"}]},"valueCodeableConcept":{"coding":[{"system":"http://ncimeta.nci.nih.gov","code":"C0002600","display":"amitriptyline"}]}},{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"predicted-therapeutic-implication"}]},"valueCodeableConcept":{"coding":[{"system":"http://loinc.org","code":"LA9657-3","display":"Poor metabolizer"}]}},{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"conclusion-string"}]},"valueString":"For amitriptyline, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for- tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations."}]}